Pharmaceutical News

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named One of the World’s Most Sustainable Companies by TIME for Third Consecutive Year...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 12,600 shares of the Company’s common stock at an exercise price per share of $29.73, which was...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Monday, August 3, 2026, at 4:30 p.m. ET,...

PLANO, Texas--(BUSINESS WIRE)--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the expansion of its leadership team with the appointments of Dr. Teji Singh, M.D., as Chief Medical Officer; David Chapman as Senior Vice President of Operations; Dr. Karin Lucas, Ph.D., as Vice President of Medical Affairs; and Maggie Loeffler, CPA, as Vice President of Finance & Administration. The...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented this week at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil, from the phase IIIb VOGUE study. Data show that Dovato (dolutegravir/lamivudine (DTG/3TC)) demonstrated non-inferior efficacy to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)) in treatment-naïve adults living with...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--SCIEX helps clinical labs move from sample to answer faster with new software and LC solutions....

RIO DE JANEIRO--(BUSINESS WIRE)--Today at the 2026 International AIDS Conference, Grindr for Equality committed to connecting ten million LGBTQ+ people to HIV prevention by 2028, leveraging its platform reach to advance the global effort to end HIV by 2030. The commitment is rooted in Closing the Gap, a new Grindr for Equality report drawing on survey data from Grindr users across ten countries. The central finding is consistent across countries: people know about PrEP but they are not taking i...

NEW YORK--(BUSINESS WIRE)--Segal, a leading benefits and HR consulting firm, today issued the 2027 Segal Health Plan Cost Trend Survey. The 30th annual survey report reveals that health plan cost trends for employer-sponsored benefits are approaching their highest levels in 15 years, with the median trend for medical plans expected to reach 9.9 percent. Segal’s comprehensive survey represents over 80 percent of the commercially insured and self-insured market and reveals a variety of forces acc...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--LAPIX Therapeutics has appointed Abbas Kazimi, Chief Executive Officer of Nimbus Therapeutics, to its Board of Directors as the Company advances its TIM 3/4 agonist program through Phase 1b clinical trials in rheumatoid arthritis (RA) and atopic dermatitis (AD). Kazimi brings more than two decades of biotechnology leadership experience spanning company building, corporate strategy, financing, and drug development. As CEO of Nimbus Therapeutics, he has overseen...

MANHASSET, N.Y.--(BUSINESS WIRE)--Northwell Health’s Feinstein Institutes for Medical Research has announced the groundbreaking release of the world’s first comprehensive human vagus nerve anatomical map, an achievement set to change our understanding of the autonomic nervous system and accelerate the development of bioelectronic medicine and neuromodulation therapies. The first dataset release, meticulously collected over three years from 30 human donors encompassing 60 vagus nerves, is now wi...